comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists of semaglutide for patients type 2 diabetes in clinical practice The Role of Glucagon-Like Peptide-1
Description
What should patients ask a doctor before using GLP-1 medication
2% WL with placebo in people with obesity [68]
The decision of whether or not to restart tirzepatide after pancreatitis resolves should be made on an individual basis
J Hepatol (2019) 70:53144
Davis, D
doi: 10.1038/s41591-022-01707-4 78 US National Institutes of Health
